UCB Bullish On Bimzelx Despite Sluggish Start
Gaining Market Share In IL-17 Segment
Executive Summary
While sales for the dual interleukin-17A and IL-17F inhibitor only reached €35m last year, UCB immunology chief Emmanuel Caeymaex is confident that figure will leap over the €200m barrier in 2023, if US approval for Bimzelx for psoriasis comes in the next quarter.